Ecor1 Capital LLC recently announced the acquisition of new stake in Regulus Therapeutics Inc. (NASDAQ:RGLS). The institutional investor has increased its shareholding in the Healthcare company to 1.89 million shares with purchase of 1.89 million shares. This fresh investment now brings its stake to 6.83% valued currently at $1.42 million. In addition, Renaissance Technologies LLC raised its holdings by 39489.0 to 0.52 million shares. And G1 Execution Services LLC has lifted its position to 70641.0 shares – to 70641.0 shares.
With over 1.29 million Regulus Therapeutics Inc. (RGLS) shares trading Wednesday and a closing price of $0.84 on the day, the dollar volume was approximately $1.08 million. The shares have shown a positive weekly performance of 23.98% and its price on 07/08/20 lost nearly -1.53%. Currently, there are 24.06M common shares owned by the public and among those 16.45M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: Several analysts who have offered their price forecasts for RGLS have a consensus price objective of $1.00. The analysts have set the share’s price value over the next 12 months at a high of $1.50 and a low of $0.50 should the stock experience a downside. Incidentally, analysts’ outlook for the Regulus Therapeutics Inc. stock is 2.70 for the next 12 months. The average price target is 16.0% above its last price level and an upside to the estimated low will see the stock lose -68.0% over that period. But an upside of 44.0% will see the stock hit the forecast high price target while mean target price for the stock is $1.00.
Insiders at the company have transacted a total of 14 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 2 of these insider trades were purchases, accounting for 1,072,260 shares. Insider sales of the common stock occurred on 12 occasions, with total insider shares sold totaling 44,165 shares.
The top 3 mutual fund holders in Regulus Therapeutics Inc. are Vanguard Extended Market Index Fu, Fidelity Extended Market Index Fu, and Fidelity Nasdaq Composite Index F. Vanguard Extended Market Index Fu owns 32503.0 shares of the company’s stock, all valued at over $24377.0. The company has a total holdings of about 0.12% of the shares outstanding. Fidelity Extended Market Index Fu has total holdings of 30166.0 shares valued at over $22625.0 and representing 0.11% of the shares outstanding. Fidelity Nasdaq Composite Index F has total holdings to over 26459.0 shares at a value of $19844.0. Fidelity Nasdaq Composite Index F now owns shares totaling to 0.10% of the shares outstanding.
Shares of Regulus Therapeutics Inc. (NASDAQ: RGLS) opened at $0.838, down -$0.02 from a prior closing price of $0.86. However, the script later closed the day at $0.84, down -1.53%. The company’s stock has a 5-day price change of 23.98% and 83.20% over the past three months. RGLS shares are trading -5.07% year to date (YTD), with the 12-month market performance down to -33.47% lower. It has a 12-month low price of $0.43 and touched a high of $1.74 over the same period. Currently, 1.29 million shares have been traded, compared to an average intraday trading volume of 1.53 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 2.16%, 16.42%, and 14.10% respectively.
Institutional ownership of Regulus Therapeutics Inc. (NASDAQ: RGLS) shares accounts for 35.30% of the company’s 24.06M shares outstanding. Mutual fund holders own 14.45%, while other institutional holders and individual stakeholders account for 17.00% and 0.36% respectively.
It has a market capitalization of $23.89M and a beta (3y monthly) value of 2.02. The stock’s earnings-per-share (ttm) stands at -$1.04. The company has a Quick Ratio of 1.70 with the debt-to-equity ratio at 0.98. Price movements for the stock have been influenced by the stock’s volatility, which stands at 11.22% over the week and 11.34% over the month.
Analysts forecast that Regulus Therapeutics Inc. (RGLS) will achieve an EPS of -$0.11 for the current quarter, -$0.21 for the next quarter and -$0.75 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.22 while analysts give the company a high EPS estimate of $0.16. Comparatively, EPS for the current quarter was -$0.3 a year ago. Earnings per share for the fiscal year are expected to increase by 80.70%, and -10.30% over the next financial year. EPS should shrink at an annualized rate of 39.60% over the next five years, compared to 41.30% over the past 5-year period.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 4 brokerage firm advisors rate Regulus Therapeutics Inc. (RGLS) as a “Moderate Buy” at a consensus score of 2.70. Specifically, 1 Wall Street analysts polled rate the stock as a buy, while 3 of the 4 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the RGLS, a number of firms have released research notes about the stock. B. Riley FBR Inc. stated their Neutral rating for the stock in a research note on March 28, 2018, with the firm’s price target at $1. Leerink Partners coverage for the Regulus Therapeutics Inc. (RGLS) stock in a research note released on January 05, 2018 offered a Outperform rating with a price target of $2. Chardan Capital Markets was of a view on June 13, 2017 that the stock is Buy, while Wedbush gave the stock Outperform rating on March 06, 2017, issuing a price target of $8- $6. Wells Fargo on their part issued Market Perform rating on January 30, 2017.